SR-11237 is a selective pan retinoid X receptor (RXR) agonist with no retinoid A receptor (RAR) activity. .

A selective prostaglandin E receptor subtype 4 (EP4) antagonist with pKi of 8.5.

A selective small molecule toward Tec kinase-mediated tyrosine phosphorylation of FGF2 with IC50 of 11.7 uM.

A selective small molecule toward Tec kinase-mediated tyrosine phosphorylation of FGF2 with IC50 of 7.0 uM.

A selective small-molecule inhibitor of tisoprenylcysteine carboxyl methyltransferase (Icmt) with IC50 <200 nM, does not inhibit other enzymes (farensyltransferase, geranylgeranyltransferase type I, and Rce1) at concentrations up to 50 uM.

A selective TLR8 agonist that induces activation of NF-κB at 0.4 uM.

A selective TRPM8 channel blocker with pEC50 of 6.91 in Ca(2+) influx assay, with no activity for TRPV4 (pEC50<4.6).

A selective α2A receptor agonist that can reduce peripheral sympathetic outflow and thus cansues a reduction in peripheral sympathetic tone.

A selective β1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension..

A selective Δ6 desaturase inhibitor that displays selectivity over Δ5 and Δ9 desaturases

A selective, G protein-biased µ-opioid receptor agonist, does not promote the development of opioid-induced mechanical allodynia (OIMA) and rapidly reverses allodynia in vivo..

A selective, G protein-biased µ-opioid receptor agonist, does not promote the development of opioid-induced mechanical allodynia (OIMA) and rapidly reverses allodynia in vivo..

A selective, nonpeptidic, noncompetitive BACE1 inhibitor with IC50 of 3.15 uM in cell-free assays.

A selective, orally active JAK3 inhibitor that reduces IL-2-mediated JAK3 tyrosine phosphorylation with cellular IC50 of 10-20 uM.

A selective, orally bioactive and brain permeable δ-secretase (AEP.

A selective, reversible, high-affinity PAI-1 inhibitor that prevents PAI-1 from inactivating tPA and uPA with similar potency (IC50=30 and 25 nM, respectively).

A selective, small molecule inhibitor of PIP5K1C with IC50 of 41 nM, does not ihibits other lipid kinases including PI3Ks.

A selective, water-soluble, in vivo long-lasting AMPA antagonist with Ki of 43 nM.

A sepecific, orally bioavailable SHIP1 activator with no effect on functional androgen, oestrogen, oestrogen-related receptor α, glucocorticoid, mineralocorticoid and progesterone receptor at 30 uM.

A serine protease inhibitor that inhibits the esterolytic activity of factor D (IC50=96 nM) and C1s (IC50=1.6 nM).

A short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD)..

A short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD)..